Semaglutide contained oral prolonged-release preparation and preparation method thereof

A sustained-release preparation, semaglutide technology, applied in medical preparations containing active ingredients, medical preparations with non-active ingredients, pill delivery, etc., can solve the problem of high cost for patients

Inactive Publication Date: 2018-10-02
南京星银药业集团有限公司
View PDF8 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the oral dosage form of semaglutide requires 300 times the dose of active ingredient than the subcutaneous

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Semaglutide contained oral prolonged-release preparation and preparation method thereof
  • Semaglutide contained oral prolonged-release preparation and preparation method thereof
  • Semaglutide contained oral prolonged-release preparation and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Example Embodiment

[0031] Example 1

[0032] Prescription of oral sustained-release preparations containing semaglutide (content per tablet)

[0033]

[0034] The original and auxiliary materials were passed through an 80-mesh sieve, and set aside, and the prescription amount of 1000 pieces of samples was configured.

[0035] ①Weigh semaglutide, metformin, cellulose acetate, ethyl cellulose, and polyethylene glycol according to the prescription amount; dissolve polyethylene glycol, semaglutide, and metformin in 1 mL of water as the internal water phase W1 ; Dissolve cellulose acetate in 10 mL of dichloromethane as the organic phase O; dissolve polyvinyl alcohol in 50 mL of water as the outer water phase W2;

[0036] ②Add the internal water phase W1 to the organic phase O, and phacoemulsify at a power of 250W for 10 minutes to form uniform colostrum W1 / O;

[0037] ③The colostrum W1 / O is added to the outer water phase W2, and the power is 250W phacoemulsified for 10 minutes to form a double emulsion W1 / O / W...

Example Embodiment

[0042] Example 2

[0043] Prescription of oral sustained-release preparations containing semaglutide (content per tablet)

[0044]

[0045] The original and auxiliary materials were passed through an 80-mesh sieve, and set aside, and the prescription amount of 1000 pieces of samples was configured.

[0046] ①Weigh semaglutide, ciglitazone, cellulose acetate, polyethylene, and Tween-80 according to the prescription amount; dissolve Tween-80, semaglutide, and ciglitazone in 2 mL of water as Inner water phase W1; cellulose acetate and polyethylene are dissolved in 10 mL of dichloromethane as the organic phase O; polyvinyl alcohol is dissolved in 100 mL of water as the outer water phase W2;

[0047] ②Add the internal water phase W1 to the organic phase O, and phacoemulsify at 300W for 8min to form uniform colostrum W1 / O;

[0048] ③The colostrum W1 / O is added to the outer water phase W2, and the power is 300W phacoemulsified for 8 minutes to form a double emulsion W1 / O / W2;

[0049] ④The doub...

Example Embodiment

[0053] Example 3

[0054] Prescription of oral sustained-release preparations containing semaglutide (content per tablet)

[0055]

[0056] The original and auxiliary materials were passed through an 80-mesh sieve, and set aside, and the prescription amount of 1000 pieces of samples was configured.

[0057] ①Weigh semaglutide, pioglitazone, ethyl cellulose, polyethylene, and mannitol according to the prescription amount; dissolve mannitol, semaglutide, and pioglitazone in 2 mL of water as the internal water phase W1; ethyl cellulose , Polyethylene is dissolved in 10mL of dichloromethane, as the organic phase O; Polyvinyl alcohol is dissolved in 100mL of water, as the outer water phase W2;

[0058] ②Add the internal water phase W1 to the organic phase O, and phacoemulsify at a power of 350W for 7 minutes to form uniform colostrum W1 / O;

[0059] ③The colostrum W1 / O is added to the outer water phase W2, and the power is 350W for phacoemulsification for 7 minutes to form a double emulsion ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a semaglutide contained oral prolonged-release preparation and a preparation method thereof. The semaglutide contained oral prolonged-release preparation is characterized in that a drug active component is semaglutide as a GLP-1 analogue and is also prepared from a sulfonylurea, biguanide or thiazolidinedione blood sugar lowering drug which has the synergistic effect withthe semaglutide; the drug active component is wrapped with a sustained release carrier to prepare a sustained release microsphere, and then the sustained release microsphere is mixed and pressed witha pharmaceutically acceptable auxiliary material to form a tablet with a certain shape for orally use, so that the long-term sustained release effect is exerted. By adopting the prepared oral prolonged-release preparation, the conventional administration way of a polypeptide drug is changed, the action time of the polypeptide drug is prolonged, the medication compliance of a patient with diabetesmellitus is obviously improved, and the therapeutic effect is improved.

Description

technical field [0001] The invention relates to the technical field of pharmaceutical preparations, in particular to an oral sustained-release preparation containing semaglutide and a preparation method thereof. Background technique [0002] With the development of the global economy and the improvement of living standards, changes in lifestyle and population aging, the prevalence of diabetes is on the rise worldwide, becoming another chronic disease that seriously endangers public health after cardiovascular and cerebrovascular diseases and tumors. non-communicable diseases. The main types of diabetes include type Ⅰ diabetes, type Ⅱ diabetes, gestational diabetes and other special types of diabetes. Among them, type Ⅱ diabetes accounts for about 95%. At present, there are mainly four types of drugs that can be used to reduce blood sugar levels in patients with type 2 diabetes: sulfonylurea hypoglycemic drugs, such as gliquidone, glimepiride, and gliclazide; biguanide hypo...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/26A61K47/38A61K47/32A61K47/06A61K47/18A61K38/26A61P3/10A61K31/425A61K31/4439A61K31/155
CPCA61K9/0002A61K9/0053A61K9/2013A61K9/2027A61K9/2054A61K9/2077A61K31/155A61K31/425A61K31/4439A61K38/26A61K2300/00
Inventor 刘铠豪赵文华
Owner 南京星银药业集团有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap